Skip to main content
. 2013 Jul 26;8(7):e70712. doi: 10.1371/journal.pone.0070712

Figure 5. SAHA treatment lowers the mRNA expression of ELOVL1 and ELOVL3 in Abcd1-deficient U87 astrocytes and B12 oligodendrocytes.

Figure 5

Abcd1-deficient U87 astrocytes and B12 oligodendrocytes were treated dose-dependently with SAHA for 3 days and mRNA expression of ELOVL1 and ELOVL3 were quantified in control, NT, and untreated/treated Abcd1-deficient U87 astrocytes (A and B) and B12 oligodendrocytes (C and D) by qRT-PCR normalized to GAPDH. Data are represented as mean±SD. *P<0.001 Abcd1-deficient cells compared with control or NT cells; **P<0.02 SAHA (5.0 µM) treatment compared with untreated Abcd1-deficient U87 astrocytes; ***P<0.001 SAHA treatment compared with untreated Abcd1-deficient cells. NS, non-significant; SA5, SAHA (5 µM).